SHR2150
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
December 28, 2021
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy Subjects
(clinicaltrials.gov)
- P1; N=37; Completed; Sponsor: Jiangsu HengRui Medicine Co., Ltd.; Enrolling by invitation ➔ Completed
Clinical • Trial completion • Human Immunodeficiency Virus • Infectious Disease • IFNG
December 20, 2021
A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers
(clinicaltrials.gov)
- P1; N=20; Active, not recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.; Not yet recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • Human Immunodeficiency Virus • Immunology • Infectious Disease
December 02, 2021
A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers
(clinicaltrials.gov)
- P1; N=20; Not yet recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Clinical • New P1 trial • Human Immunodeficiency Virus • Immunology • Infectious Disease
1 to 3
Of
3
Go to page
1